Fintech▲ 40

Transcenta Therapeutics Appoints New Executive

Globenewswire·March 30, 2026 at 12:30 PM

Transcenta Therapeutics has announced the appointment of Dr. Christopher Hwang to a key executive position within the company. This strategic hire is expected to bolster the leadership team as Transcenta continues to advance its global biopharmaceutical pipeline. The company, listed on the HKEX as 06628, is focused on developing innovative therapies for various diseases. Dr. Hwang's expertise is anticipated to contribute significantly to the company's ongoing research and development efforts and its overall strategic objectives.

Tickers

$06628

Transcenta Therapeutics Appoints New Executive

NY Fed: Mobile Sports Betting Increases Credit Delinquency

Labor Department Eases 401(k) Alternative Investment Access

US rule may open trillions in 401(k) to crypto

Businesses Adapt AI Budgeting to Usage-Based Pricing